# OnCo record idea-crc-ctdna-de-escalation-beyond-stage-ii (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-crc-ctdna-de-escalation-beyond-stage-ii/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-crc-ctdna-de-escalation-beyond-stage-ii" ;
  schema:name "Take ctDNA-guided de-escalation beyond stage II, and stop escalating on a positive result until a trial says it helps"@en ;
  schema:description "A blood test after surgery already lets stage II colon cancer patients skip chemotherapy safely. The same test in stage III would spare far more people, and the unproven half, giving more chemotherapy to those who test positive, has so far changed nothing."@en ;
  schema:url <https://onco.cc/ideas/idea-crc-ctdna-de-escalation-beyond-stage-ii/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://europepmc.org/article/MED/35657320>, <https://europepmc.org/article/MED/36646802>, <https://clinicaltrials.gov/study/NCT05174169>, <https://clinicaltrials.gov/study/NCT04120701> ;
  onco:tag "colorectal-evidence" ;
  onco:related <https://onco.cc/roadmaps/colorectal-roadmap/>, <https://onco.cc/roadmaps/ctdna-tests/>, <https://onco.cc/ideas/idea-ctdna-guided-adjuvant-crc/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/colon-cancer/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/chemotherapy/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/drugs/signatera/>, <https://onco.cc/terms/ngs/> ;
  onco:drugs <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:companies <https://onco.cc/companies/natera/>, <https://onco.cc/companies/guardant-health/> ;
  onco:terms <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/neoadjuvant-adjuvant/> ;
  onco:trials <https://onco.cc/trials/dynamic/>, <https://onco.cc/trials/circulate-japan/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-dormancy-mrd/>, <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-tie-dynamic-ctdna-guided-adjuvant-stage-ii-colon-nejm-2022/>, <https://onco.cc/key-papers/paper-kotani-galaxy-molecular-residual-disease-nat-med-2023/>, <https://onco.cc/key-papers/paper-tie-ctdna-minimal-residual-disease-stage-ii-colon-sci-transl-med-2016/>, <https://onco.cc/key-papers/paper-idea-duration-adjuvant-stage-iii-colon-nejm-2018/> .